With the World Health Organization and Global Governments sounding alert bells to fast track possible vaccines and drug treatments for the COVID-19 Pandemic. The race is on to find an innovative lifesaving Panacea for the 7.8 billion people around the world.

We have found a company teaming up for research with the Centers for Disease Control (CDC), the National Institute of Allergy and Infectious Diseases (NIAID), the US Department of Defense, as well as other key federal government agencies.

WPD Pharmaceuticals Inc has a promising new drug candidate called WP1122 that could be the Panacea the world is looking for. According to recent published news WP1122 is showing considerable promise in pre-clinic  studies as a novel therapy for treating viruses, including Coronavirus, a.k.a. COVID-19.

The Opportunity:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

  • Over 14 million dollars in non-dilutive research financing through European Union government grants
  • The company is in experienced into advanced oncology R&D
  • 10 novel drug candidates, 4 in clinical development stage
  • $89M invested in pipeline focused on melanoma, brain cancer, leukemia, pancreatic cancer
  • Ongoing collaborations with MD Anderson Cancer Center, Mayo Clinic, Emory University, Wake Forest
  • Targeting multiple multi-billion-dollar market opportunities
  • Insiders control nearly 40% of equity
  • Just entered into agreement with leading research facility in US to conduct research on patented portfolio of molecular inhibitors, including WP1122, for anti-viral properties against a range of viruses, including coronavirus.

Learn More About WCOTF at your brokerage today!

A world class management team with a proven
winning track record

Dr. Waldemar Priebe, Ph.D.  FOUNDER, CHAIRMAN OF SCIENTIFIC ADVISORY
A world-renowned medicinal chemist, he is also an extraordinarily successful entrepreneur in the life sciences industry, which investors should keep in mind. In fact, he has founded no less than six pharmaceutical companies. Among them is Reata Pharmaceuticals (NASDAQ: RETA), which has become a pharmaceutical powerhouse with a market capitalization on NASDAQ of over US $4.6 billion, as well as two other Nasdaq-listed pharmaceutical success stories.

Mr. Walter Klemp BOARD MEMBER
Walter Klemp has 29 years of experience in start-up and high-growth companies, the past nine of which have been spent developing FDA-approved dermatology therapy devices and topical compounds. Mr. Klemp has been the Founder and CEO for Moleculin Biotech, Inc. (Nasdaq: MBRX) since 2007 and also President and CEO of Zeno Corporation from 2004 to 2010, where he successfully developed and marketed a number of dermatology devices and drugs from concept through FDA approval. He is also a Founder and Executive Chairman of Soliton, Inc. (Nasdaq: SOLY), a medical device company started in 2012.

The Company:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

As long as cancer and infectious disease exists, the biggest investment opportunity in human history is still out there for the taking. Cancer and infectious diseases impacts more lives and in more profound ways than any other serious health condition. And we still haven’t really figured out how to beat it.

The company is developing novel clinical solutions to a variety of cancer types right now, where a top research team has been pursuing a unique path characterized by biological and chemical molecules designed to target molecular receptors in the cancer cells themselves.

Based on its top quality research and progress in developing pipeline assets, the company has qualified for nearly $30 million in grant-based funding, and earned partnerships with top-tier cancer research facilities, including the MD Anderson Cancer Center, the Mayo Clinic, Emory University, and Wake Forest University.

The company already has 4 drugs in full clinical evaluation, meaning that the next steps could include some degree of validation of its research, leading to a massive upward repricing of shares of the stock. Given its approach, any validation coming from near-term data would have the impact of presenting potential cash flows from an eventual marketing of that drug. But more importantly, it would also suggest a big jump in the odds that its other 9 compounds might find success as well because the first big validation in clinical testing validates the whole pipeline for a biotech.

The market would also start to contemplate the potential that the company might become an M&A target from one of the big pharma giants out there who regularly gobble up smaller oncology firms following initial successes in clinical testing.

In addition, it’s always a great sign when a large fraction of the equity in a company like this – where the future is binary and unknown – is owned by insiders who know the most about what’s really going on underneath the hood in terms of the science backing its main assets. In this case, almost 40% of the company is owned by the people who know the most about it.

More to the point, unless you have been living on another planet, then you are aware that everything right now revolves around the devastating COVID-19 pandemic. This disease is quite literally reshaping the global economic landscape as it ravages communities around the world. There are nearly 400,000 confirmed cases of this terrible disease, and experts see that number rising into the hundreds of millions over coming months.

According to leading Harvard epidemiologist, professor Marc Lipsitch, as expressed in The Atlantic on February 24, as many as 40 to 70 percent of the world’s population may become infected with the virus that causes COVID-19 within the next 12 months. Other leading epidemiology experts have made similar predictions, implying a dramatic jump in the number of cases of COVID-19 across most communities in the US over the next 12 months, before an effective vaccine can be created, tested, approved, and mass manufactured.

WPD just released news of an agreement that puts the company on the frontline as a key resource in battling this tragic outbreak as tests get underway to establish one of its leading assets, WP1122, for anti-viral properties against a range of viruses, including coronavirus.

 

 


Symbol:  WCOTF
Company:  WPD Pharmaceuticals Inc.
Quote:  http://finance.yahoo.com/q?s=WCOTF
Latest News: 
http://finance.yahoo.com/q/h?s=WCOTF+Headlines
Company Website:
https://www.wpdpharmaceuticals.com

Learn More About WCOTF at your brokerage today!

Inherent Advantages:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) provides biotechnology research and development services with a focus on oncology, namely discovery and development of medicinal products involving biological compounds and molecules. WPD has 10 novel drug candidates with 4 that are in clinical development stage.

The big idea here with most of this pipeline is about novel molecules driven by designer proteins that work like keys to open locks at the membrane level to reach specific receptors essential to the development of malignant tumors.

For the most part, the company represents an acquisition vehicle for promising pre-clinical compounds that fit this sort of novel and clinically robust description. The stock is backed by insiders and on top of capital blocks that represent the artifacts of its asset acquisition process thus far.

As noted above, this puts it mostly in the hands of people who want to see it succeed, and they remain involved presumably because they believe it can and will.

Part of that optimism is driven by its strong hand of strategic partnerships, including big name brands such as Wake Forest, the Mayo Clinic, and the Polish government.

The other big tailwind here is the company’s track record at securing grant funding – already almost $30 million so far. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland. That adds a layer of non-dilutive funding that should continue to support an argument for a higher multiple on forward cash flows from marketable drugs as the pipeline progresses.

The Big Picture:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

Moreover, WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It focuses on developing biological and chemical molecules involved in targeted therapy for brain glioma and other central nervous system cancers.

The company offers drug production, validation, preclinical trials, and clinical trials solutions. The drugs deal with melanoma, brain cancer, leukemia, and pancreatic cancer.

These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.

The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes 30 countries in Europe and Asia, including Russia.

The Talent:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

Mariusz Olejniczak, CEO of WPD Pharmaceuticals,
Mr. Olejniczak is an experienced professional in medicinal products, medical devices, supplements and plant protection products R&D at every stage – from planning and scientific advice through supervision to the closure and finalization of the project. He is a founder of several start-ups in the e-health industry and a member of the board and supervisory board of several R&D companies. He was also responsible for the acquisition of Bioscience SA. (a CRO operating in Poland) by the Neuca group. As a graduate in biotechnology at the University of Life Sciences in Poznań, he has developed his skills through postgraduate studies. He is author of the publication “Change of the product development model as an opportunity for the Polish pharmaceutical industry” (in Polish), a member of the editorial committee of the book “Clinical Trials” (in Polish) and a lecturer in post-graduate study programs.

Beata Pajak, Chief Scientific Officer,
Mr. Pajak is a biotechnologist with experience in the field of medical biology, including: oncology, virology, pathophysiology of neurodegenerative diseases and skeletal muscle physiology. Expert in the field of signal pathways, mechanisms of programmed cell death, chemo- and immuno-resistance of cancer cells. Head and team member in research and implementation projects. Author and co-author of publications and conference reports. Laureate of L’Oreal UNESCO “For Women and Science” and “Polityka” journal “Stay with us” scholarships, MNiSW Scholarship for Young Outstanding Scientists, 1st Award of the Hasco-Lek Foundation for the doctoral dissertation and Gedeon Richter company distinction “With a passion for the future”.

Dr. Waldemar Priebe, Ph.D.  FOUNDER, CHAIRMAN OF SCIENTIFIC ADVISORY
A world-renowned medicinal chemist, he is also an extraordinarily successful entrepreneur in the life sciences industry, which investors should keep in mind. In fact, he has founded no less than six pharmaceutical companies. Among them is Reata Pharmaceuticals (NASDAQ: RETA), which has become a pharmaceutical powerhouse with a market capitalization on NASDAQ of over US $4.6 billion, as well as two other Nasdaq-listed pharmaceutical success stories.

Mr. Walter Klemp BOARD MEMBER
Walter Klemp has 29 years of experience in start-up and high-growth companies, the past nine of which have been spent developing FDA-approved dermatology therapy devices and topical compounds. Mr. Klemp has been the Founder and CEO for Moleculin Biotech, Inc. (Nasdaq: MBRX) since 2007 and also President and CEO of Zeno Corporation from 2004 to 2010, where he successfully developed and marketed a number of dermatology devices and drugs from concept through FDA approval. He is also a Founder and Executive Chairman of Soliton, Inc. (Nasdaq: SOLY), a medical device company started in 2012.

The Catalysis:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

Most recently, the company entered into an agreement with a leading government-funded research facility in the United States to conduct research on its patented portfolio of molecular inhibitors, including drug candidate, WP1122, for anti-viral properties against a range of viruses, including coronavirus, placing the company on the frontline as a resource in the battle against the COVID-19 pandemic.

Mariusz Olejniczak, chief executive officer of WPD, commented: “We are eager for testing to begin on our WP1122 drug for anti-viral properties against viruses, including the prevalent coronavirus. The in vivo research supporting the use of 2-DG as dual inhibitor of glycolysis and glycosylation to defeat viruses like coronavirus through multiple effects critical to the progression of viral infection is promising. We believe that during this difficult time, it is the responsibility of every biotech company to remain committed to research and test the entire drug portfolio to find alternative treatment for patients.”

Before that, the company recently put out an update on the clinical drug studies of Annamycin in Acute Myeloid Leukemia (AML). WPD’s license partner Moleculin Biotech, Inc, (“Moleculin”)(Nasdaq:MBRX) disclosed additional positive interim safety and efficacy data from one of the two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory AML.

According to the release, the Phase 1 portion of these clinical trials is designed to establish the safety of Annamycin and to determine the Recommended Phase 2 Dose to be used in the Phase 2 portion of the trials. While the Primary Endpoint of the Phase 1 portion is safety, a Secondary Endpoint is the assessment of efficacy generally defined as an improvement in bone marrow biopsy results sufficient to qualify patients for a potentially curative bone marrow transplant.

The good news is that the primary endpoint has been met so far with no adverse events. But even better, 4 of the 10 patients saw clear signs of efficacy as well, which helps to fuel optimism for phase 2 research, where breakthroughs regularly get noticed by the markets.

Just ahead of that news, the company announced that on February 6, 2020 Wake Forest University received a notice of allowance from the United States Patent and Trademark Office patent for antibodies against human and canine il-13ra2 (under application number 15/835,566). The patent is exclusively licensed by Wake Forest to WPD, and patent relates to the WPD101, WPD102 and WPD103 drug candidates, used in the therapy of glioblastoma multiform and other tumors. Within the WPD 101,102,103 portfolio of drug candidates, WPD has 40 patents issued or filed in key territories including the US, Canada, and the EU.

This is great news as it shores up any possible concerns about IP for core assets related to this judgment.

And, just after those updates, the company put out word that, through its license partner, CNS Pharmaceuticals, Inc. (“CNS”)(Nasdaq:CNSP), it received positive feedback from the U.S. Food and Drug Administration (“FDA”) for its Pre-IND (Investigational New Drug) meeting proposal to use a lyophilized drug product, Berubicin, in Phase II clinical trials. Berubicin was developed at the largest cancer treatment and research institute in the world, and has been shown to get across the blood brain barrier and kill brain tumor cells not reachable by other therapies. Berubicin may become an effective treatment against glioblastoma, the most aggressive type of brain cancer.

According to the release, in its positive response to the previously submitted Pre-IND request, the FDA indicated that the proposal to use a lyophilized drug product in the Phase II clinical trial appears reasonable. The FDA recommended that the existing supply of Berubicin be reprocessed by batch recrystallization. Furthermore, the FDA noted that the requested dosage regimen, which will be based on the Reata Phase I trial, was reasonable. The Company plans to reprocess its existing supply of Berubicin ahead of its upcoming potential Phase II study.

We can expect further substantive updates as the company moves its pipeline closer to potential breakthrough results.

Technical Analysis:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

With an early-stage biotech, technical analysis is rarely a defining causal factor. There are many binary future catalysts that will play out without the input of technical analysts.

That said, the stock has pulled back to a key zone. Money flows have powered it from this zone before, and they may do it again.

Overall, there’s very little to go on here as far as chart history, indicator readings, patterned activity, or the like. But what we do see here is clearly in line with the idea that we are seeing a pullback in a bullish technical context that has become oversold on a short-term basis at clear chart support.

Learn More About WCOTF at your brokerage today!

About WCOTF:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

WCOTF (WPD Pharmaceuticals Inc.) provides biotechnology research and development services with a focus on oncology, namely discovery and development of medicinal products involving biological compounds and molecules.

The company offers drug production, validation, preclinical trials, and clinical trials solutions. The drugs deal with melanoma, brain cancer, leukemia, and pancreatic cancer.

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 10 novel drug candidates with 4 that are in clinical development stage.

These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.

The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes 30 countries in Europe and Asia, including Russia.

Key Points:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

  • WCOTF has amassed IP rights to promising preclinical and clinical oncology therapy candidates that are rapidly moving toward potential breakthrough status.
  • WCOTF has now officially stepped onto the playing field in the battle against COVID-19.
  • WCOTF has major name brand strategic partners, including the MD Anderson Cancer Center, the Mayo Clinic, Emory University, Wake Forest University, and the government of Poland.
  • WCOTF is backed largely by engaged insiders, stakeholders, and non-dilutive grand funding, suggesting confidence by the people with the most knowledge of the company and its assets.
  • WCOTF recently received USPTO allowance to shore up its IP claims to its top pipeline assets.
  • WCOTF is targeting a multiple multi-billion-dollar industries with its portfolio of biological assets.
  • WCOTF shares are pulling back to key support as new catalysts line up to spark potential resurgent flows into the stock.

Conclusion:  WPD Pharmaceuticals Inc. (OTCMKTS:WCOTF) (CSE:WBIO)

WPD Pharma has a very diverse and promising pipeline of early clinical and preclinical assets representing a novel approach to therapeutics in some massive oncology end markets. We are quickly approaching catalysts that will possibly force the market to take notice of both commercial and M&A potential here that could drive shares of the stock a great deal higher under the right conditions.

The cap table is controlled by stakeholders and insiders, demonstrating a strong signal about the company’s long-term prospects. And it has a repeatedly proven inside track to additional non-dilutive funding through grants and a powerful network of strategic partnerships with real clout and reputational status.

With the stock pulling back to key chart support and some big catalysts lined up ahead, it deserves a long hard look.

 

 


Symbol:  WCOTF
Company:  WPD Pharmaceuticals Inc.
Quote:  http://finance.yahoo.com/q?s=WCOTF
Latest News: 
http://finance.yahoo.com/q/h?s=WCOTF+Headlines
Company Website:
https://www.wpdpharmaceuticals.com

Learn More About WCOTF at your brokerage today!

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.